{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:44:44Z","timestamp":1770511484662,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.schres.2011.03.033","type":"journal-article","created":{"date-parts":[[2011,4,25]],"date-time":"2011-04-25T00:35:41Z","timestamp":1303691741000},"page":"34-39","source":"Crossref","is-referenced-by-count":8,"title":["How do clinical trial participants compare to other patients with schizophrenia?"],"prefix":"10.1016","volume":"130","author":[{"given":"Paul G.","family":"Barnett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer Y.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Rosenheck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2011.03.033_bb0005","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.4088\/JCP.v68n0808","article-title":"Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study","volume":"68","author":"Bai","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2011.03.033_bb0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.2517-6161.1964.tb00553.x","article-title":"An analysis of transformations","volume":"26","author":"Box","year":"1964","journal-title":"J. Royal Stat. Soc. Series B (Method.)"},{"key":"10.1016\/j.schres.2011.03.033_bb0015","series-title":"Regression Analysis of Count Data","author":"Cameron","year":"1998"},{"key":"10.1016\/j.schres.2011.03.033_bb0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euroneuro.2004.07.003","article-title":"Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets","volume":"15","author":"Chue","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.schres.2011.03.033_bb0025","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2165\/00019053-200523001-00006","article-title":"Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada","volume":"23","author":"Chue","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.schres.2011.03.033_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhealeco.2004.08.001","article-title":"Do new prescription drugs pay for themselves? The case of second-generation antipsychotics","volume":"24","author":"Duggan","year":"2005","journal-title":"J. Health Econ."},{"key":"10.1016\/j.schres.2011.03.033_bb0035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clinthera.2005.02.003","article-title":"Assessment of compliance with antipsychotic treatment and resource utilization in a medicaid population","volume":"27","author":"Eaddy","year":"2005","journal-title":"Clin. Ther."},{"issue":"Suppl 1","key":"10.1016\/j.schres.2011.03.033_bb0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00019053-200523001-00007","article-title":"Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA","volume":"23","author":"Edwards","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.schres.2011.03.033_bb0045","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4088\/JCP.v64n1017","article-title":"Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic","volume":"64","author":"Fleischhacker","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2011.03.033_bb0050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1034\/j.1600-0447.2002.00242.x","article-title":"Randomized controlled trials in schizophrenia: a critical perspective on the literature","volume":"105","author":"Gilbody","year":"2002","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2011.03.033_bb0055","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1176\/appi.ajp.161.4.692","article-title":"Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia","volume":"161","author":"Gilmer","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.03.033_bb0060","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00004714-200012000-00019","article-title":"Selection bias in clinical trials with antipsychotics","volume":"20","author":"Hofer","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2011.03.033_bb0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-244X-8-31","article-title":"Effectiveness of second generation antipsychotics: a systematic review of randomized trials","volume":"8","author":"Johnsen","year":"2008","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2011.03.033_bb0070","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":"Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic","volume":"160","author":"Kane","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.03.033_bb0075","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1192\/bjp.bp.105.017020","article-title":"Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study","volume":"191","author":"Keks","year":"2007","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.03.033_bb0080","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.4088\/JCP.v65n0809","article-title":"Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics","volume":"65","author":"Lindenmayer","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2011.03.033_bb0085","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0167-6296(01)00086-8","article-title":"Estimating log models: to transform or not to transform?","volume":"20","author":"Manning","year":"2001","journal-title":"J. Health Econ."},{"key":"10.1016\/j.schres.2011.03.033_bb0090","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004850-200505000-00001","article-title":"Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies","volume":"20","author":"Moller","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2011.03.033_bb0095","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1475-6773.2010.01107.x","article-title":"Relationship between clinical conditions and use of Veterans Affairs health care among Medicare-enrolled veterans","volume":"45","author":"Petersen","year":"2010","journal-title":"Health Serv. Res."},{"key":"10.1016\/j.schres.2011.03.033_bb0100","first-page":"II61","article-title":"Methods for estimating and comparing VA outpatient drug benefits with the private sector","volume":"41","author":"Render","year":"2003","journal-title":"Med. Care"},{"key":"10.1016\/j.schres.2011.03.033_bb0105","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1176\/appi.ps.54.4.508","article-title":"An economic review of compliance with medication therapy in the treatment of schizophrenia","volume":"54","author":"Thieda","year":"2003","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2011.03.033_bb0110","series-title":"CBO Paper","article-title":"Prices for brand-name drugs under selected federal programs","author":"United States Congress. Congressional Budget Office","year":"2005"},{"key":"10.1016\/j.schres.2011.03.033_bb0115","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00005650-200208000-00002","article-title":"Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission","volume":"40","author":"Valenstein","year":"2002","journal-title":"Med. Care"},{"key":"10.1016\/j.schres.2011.03.033_bb0120","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/schbul\/21.3.419","article-title":"Cost of relapse in schizophrenia","volume":"21","author":"Weiden","year":"1995","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2011.03.033_bb0125","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1176\/ps.51.1.79","article-title":"Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia","volume":"51","author":"Woods","year":"2000","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2011.03.033_bb0130","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1440-1819.2005.01390.x","article-title":"Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs","volume":"59","author":"Yang","year":"2005","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2011.03.033_bb0135","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-244X-8-72","article-title":"Costs of treating patients with schizophrenia who have illness-related crisis events","volume":"8","author":"Zhu","year":"2008","journal-title":"BMC Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996411001812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996411001812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T07:35:06Z","timestamp":1741160106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996411001812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":27,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0920996411001812"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2011.03.033","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}